Literature DB >> 26047306

Neurotrophic factors in depression in response to treatment.

Henriette N Buttenschøn1, Leslie Foldager2, Betina Elfving3, Pia H P Poulsen3, Rudolf Uher4, Ole Mors5.   

Abstract

BACKGROUND: Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor A (VEGF) have been suggested to play a role in the pathophysiology of depression. The neurotrophic model of depression hypothesises that the serum level of e.g. BDNF is decreased during depression and increased in response to treatment. The aim of the present study was to investigate BDNF and VEGF as potential predictors of response to antidepressant treatment.
METHODS: We investigated the longitudinal associations between depression scores and serum levels of these neurotrophic factors during antidepressant treatment in 90 individuals with depression of at least moderate severity. Serum levels were measured at baseline and after 8 and 12 weeks of treatment with nortriptyline or escitalopram.
RESULTS: No baseline or longitudinal correlations between depression scores and serum levels of BDNF and VEGF were found, and the baseline serum levels did not predict the MADRS depression score after 12 weeks of treatment or the improvement in depression scores. Interestingly, we observed a significant baseline and longitudinal correlation between serum levels of BDNF and VEGF. The two classes of antidepressant treatment did not affect the results differently. LIMITATIONS: Information on potential factors influencing the serum levels is missing.
CONCLUSION: Our results do not support the neurotrophic model of depression, since a significant decrease in serum BDNF and VEGF levels after 12 weeks of antidepressant treatment was observed. Our study encourages future studies with large sample sizes, more observations and a longer follow-up period.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antidepressant treatment; Brain-derived neurotrophic factor (BDNF); Depression; Longitudinal; Serum; Vascular endothelial growth factor (VEGF)

Mesh:

Substances:

Year:  2015        PMID: 26047306     DOI: 10.1016/j.jad.2015.05.027

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  15 in total

1.  A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment.

Authors:  Marina Sagud; Matea Nikolac Perkovic; Bjanka Vuksan-Cusa; Anja Maravic; Dubravka Svob Strac; Alma Mihaljevic Peles; Maja Zivkovic; Zorana Kusevic; Nela Pivac
Journal:  Psychopharmacology (Berl)       Date:  2016-06-29       Impact factor: 4.530

2.  Antidepressant Effects of the Ginsenoside Metabolite Compound K, Assessed by Behavioral Despair Test and Chronic Unpredictable Mild Stress Model.

Authors:  Wu Song; Yan Guo; Shuang Jiang; Lin Wei; Zhi Liu; Xiaoyan Wang; Ying Su
Journal:  Neurochem Res       Date:  2018-05-22       Impact factor: 3.996

3.  Fibroblast growth factor 22 is a novel modulator of depression through interleukin-1β.

Authors:  Yu-Hao Xu; Ming Yu; Hong Wei; Shun Yao; Si-Yuan Chen; Xiao-Lan Zhu; Yue-Feng Li
Journal:  CNS Neurosci Ther       Date:  2017-09-25       Impact factor: 5.243

Review 4.  Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.

Authors:  Bharathi S Gadad; Manish K Jha; Andrew Czysz; Jennifer L Furman; Taryn L Mayes; Michael P Emslie; Madhukar H Trivedi
Journal:  J Affect Disord       Date:  2017-07-05       Impact factor: 4.839

5.  Vascular endothelial growth factor plasma levels in depression and following electroconvulsive therapy.

Authors:  Karen M Ryan; Declan M McLoughlin
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-07-02       Impact factor: 5.270

6.  MicroRNA Profiling in the Medial and Lateral Habenula of Rats Exposed to the Learned Helplessness Paradigm: Candidate Biomarkers for Susceptibility and Resilience to Inescapable Shock.

Authors:  Katrine Svenningsen; Morten T Venø; Kim Henningsen; Anne S Mallien; Line Jensen; Trine Christensen; Jørgen Kjems; Barbara Vollmayr; Ove Wiborg
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

7.  Z-Guggulsterone Produces Antidepressant-Like Effects in Mice through Activation of the BDNF Signaling Pathway.

Authors:  Feng-Guo Liu; Wen-Feng Hu; Ji-Li Wang; Peng Wang; Yu Gong; Li-Juan Tong; Bo Jiang; Wei Zhang; Yi-Bin Qin; Zhuo Chen; Rong-Rong Yang; Chao Huang
Journal:  Int J Neuropsychopharmacol       Date:  2017-06-01       Impact factor: 5.176

Review 8.  Biomarkers for depression: recent insights, current challenges and future prospects.

Authors:  Rebecca Strawbridge; Allan H Young; Anthony J Cleare
Journal:  Neuropsychiatr Dis Treat       Date:  2017-05-10       Impact factor: 2.570

9.  Comparative Proteomic Characterization of Ventral Hippocampus in Susceptible and Resilient Rats Subjected to Chronic Unpredictable Stress.

Authors:  Yani Zhang; Xiaoling Zhang; Nuo Liu; Siyu Ren; Congyuan Xia; Xiong Yang; Yuxia Lou; Huiqin Wang; Ningning Zhang; Xu Yan; Zhao Zhang; Yi Zhang; Zhenzhen Wang; Naihong Chen
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

10.  Huang-Pu-Tong-Qiao Formula Ameliorates the Hippocampus Apoptosis in Diabetic Cognitive Dysfunction Mice by Activating CREB/BDNF/TrkB Signaling Pathway.

Authors:  Shu Ye; Dao-Jun Xie; Peng Zhou; Hua-Wu Gao; Meng-Ting Zhang; Da-Bao Chen; Yun-Peng Qin; Xin Lei; Xin-Quan Li; Juan Liu; Ya-Xun Cheng; Yong-Chuan Yao; Biao Cai; Guo-Ming Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.